BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8847067)

  • 1. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin.
    Attanoos RL; Goddard H; Thomas ND; Jasani B; Gibbs AR
    Histopathology; 1995 Oct; 27(4):361-6. PubMed ID: 8847067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
    Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
    Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
    Ordóñez NG
    Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
    Ordóñez NG
    Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
    Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI
    Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas.
    Osborn M; Pelling N; Walker MM; Fisher C; Nicholson AG
    Histopathology; 2002 Oct; 41(4):301-7. PubMed ID: 12383211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
    Ordóñez NG
    Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
    Ordóñez NG
    Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
    Delahaye M; van der Ham F; van der Kwast TH
    Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms.
    Attanoos RL; Dojcinov SD; Webb R; Gibbs AR
    Histopathology; 2000 Sep; 37(3):224-31. PubMed ID: 10971698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.
    Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF
    Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
    Roberts F; Harper CM; Downie I; Burnett RA
    Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.
    Roberts F; McCall AE; Burnett RA
    J Clin Pathol; 2001 Oct; 54(10):766-70. PubMed ID: 11577123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.
    Kennedy AD; King G; Kerr KM
    J Clin Pathol; 1997 Oct; 50(10):859-62. PubMed ID: 9462271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
    Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
    Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
    Naso JR; Churg A
    Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology.
    Fetsch PA; Abati A; Hijazi YM
    Cancer; 1998 Apr; 84(2):101-8. PubMed ID: 9570213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.